EUVIMEDEUVIMED entdecken
Crossref

Prognostic Factors and Real-World Outcomes in Patients Aged 65 Years and Older with Stage II and III Colon Cancer

Zeliha Birsin, Selin Cebeci, Seda Jeral, Vali Aliyev, Nebi Serkan Demirci, Özkan Alan

Eurasian Journal of Medical Investigation · 2025 · 227-239

DOI: 10.14744/ejmi.2025.155486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medical Investigation, 2025. Verfasst von Zeliha Birsin und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Colon cancer is common among older adults, yet this population is underrepresented in clinical trials. This study aimed to evaluate real-world outcomes and prognostic factors in patients aged ≥65 years with stage II and III colon cancer.

Methods

This retrospective cohort study included aged ≥65 years with stage II or III colon cancer who underwent curative-intent resection between 2010 and 2024. Clinical, pathological, and treatment-related variables were collected. Relapse-free survival (RFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression methods.

Results

Of the study population (n:218), 45% were younger than 70 years and 55% were aged ≥70 years (median age: 70). Adjuvant chemotherapy was administered to 66% overall, but less frequently in older patients (59% vs. 73%, p=0.027). Oxaliplatin-based regimens were rarely used in stage II disease (3%) but commonly given in stage III (68%, p 0.05), whereas T4 tumor stage independently predicted shorter OS (p=0.047). In stage III disease, older age (≥70; HR: 2.03, p=0.043), advanced nodal stage (HR: 2.21, p=0.013), and BMI 0.05). The addition of oxaliplatin did not provide a measurable survival benefit (p>0.05).

Conclusion

In elderly patients with colon cancer, age did not affect OS or RFS in stage II disease. In stage III, however, older age was an independent adverse factor for OS but not for RFS, while oxaliplatin did not provide additional survival benefit. These findings highlight the importance of individualized treatment decisions based on both tumor characteristics and patient factors.

Zitieren

APA

Birsin, Z., Cebeci, S., Jeral, S., Aliyev, V., Demirci, N. S., & Alan, Ö. (2025). Prognostic Factors and Real-World Outcomes in Patients Aged 65 Years and Older with Stage II and III Colon Cancer. Eurasian Journal of Medical Investigation, 227-239. https://doi.org/10.14744/ejmi.2025.155486

Vancouver

Birsin Z, Cebeci S, Jeral S, Aliyev V, Demirci NS, Alan Ö. Prognostic Factors and Real-World Outcomes in Patients Aged 65 Years and Older with Stage II and III Colon Cancer. Eurasian Journal of Medical Investigation. 2025:227-239. doi:10.14744/ejmi.2025.155486

BibTeX
@article{Birsin2025,
  author = {Birsin, Zeliha and Cebeci, Selin and Jeral, Seda and Aliyev, Vali and Demirci, Nebi Serkan and Alan, Özkan},
  title = {Prognostic Factors and Real-World Outcomes in Patients Aged 65 Years and Older with Stage II and III Colon Cancer},
  journal = {Eurasian Journal of Medical Investigation},
  year = {2025},
  pages = {227--239},
  doi = {10.14744/ejmi.2025.155486}
}
Kostenlos starten →